Arbutus Biopharma (ABUS) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ABUS Hot Sheet
Join SI Premium – FREE
Arbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of $0.01, $0.05 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $10.74 million versus the consensus estimate of $1.61 million.
For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Eversource Energy (ES) Tops Q3 EPS by 18c; offers guidance
- Suncor Energy (SU) Tops Q3 EPS by 172c
- Melco Resorts & Entertainment (MLCO) Misses Q3 EPS by 9c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
